IQAI Stock Overview
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States.
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.063|
|52 Week High||UK£0.11|
|52 Week Low||UK£0.052|
|1 Month Change||13.64%|
|3 Month Change||14.68%|
|1 Year Change||-33.51%|
|3 Year Change||177.78%|
|5 Year Change||n/a|
|Change since IPO||72.41%|
Recent News & Updates
|IQAI||GB Healthcare Services||GB Market|
Return vs Industry: IQAI underperformed the UK Healthcare Services industry which returned -7.8% over the past year.
Return vs Market: IQAI underperformed the UK Market which returned 8.3% over the past year.
|IQAI Average Weekly Movement||7.6%|
|Healthcare Services Industry Average Movement||6.1%|
|Market Average Movement||5.0%|
|10% most volatile stocks in GB Market||10.7%|
|10% least volatile stocks in GB Market||2.5%|
Stable Share Price: IQAI is more volatile than 75% of UK stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: IQAI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
IQ-AI Limited, through its subsidiaries, develops software applications for the healthcare industry in Jersey and the United States. Its products include IB Clinic, a toolkit of post-processing software plug-ins for integrating into existing medical image visualization applications; IB Rad Tech, a workflow engine that processes customized workflows; IB Neuro, which analyzes MR data sets and generates parametric perfusion maps quantifying changes in contrast over time; and IB Delta Suite that performs a various fundamental radiology operations, including image co-registration, subtraction, class map generation, and export. The company also offers IB DCE, which analyzes conventional T1 weighted images and generates an array of relevant perfusion and permeability parameters; IB Diffusion that analyzes MR diffusion-weighted images and generates apparent diffusion coefficient, extrapolated b-value, IVIM, and other parameter maps; and StoneChecker, a medical software tool to aid clinical decision making by providing information about a patient’s kidney stone.
IQ-AI Fundamentals Summary
|IQAI fundamental statistics|
Is IQAI overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IQAI income statement (TTM)|
|Cost of Revenue||UK£7.94k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0031|
|Net Profit Margin||-148.86%|
How did IQAI perform over the long term?See historical performance and comparison
Is IQ-AI undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IQAI's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IQAI's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IQAI is unprofitable, so we can't compare its PE Ratio to the European Healthcare Services industry average.
PE vs Market: IQAI is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IQAI's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IQAI is overvalued based on its PB Ratio (13.2x) compared to the GB Healthcare Services industry average (4.4x).
How is IQ-AI forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as IQ-AI has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has IQ-AI performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IQAI is currently unprofitable.
Growing Profit Margin: IQAI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IQAI is unprofitable, and losses have increased over the past 5 years at a rate of 21.6% per year.
Accelerating Growth: Unable to compare IQAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IQAI is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (26.7%).
Return on Equity
High ROE: IQAI has a negative Return on Equity (-65.01%), as it is currently unprofitable.
How is IQ-AI's financial position?
Financial Position Analysis
Short Term Liabilities: IQAI's short term assets (£413.7K) exceed its short term liabilities (£356.1K).
Long Term Liabilities: IQAI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: IQAI is debt free.
Reducing Debt: IQAI currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IQAI has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: IQAI has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.1% each year
What is IQ-AI current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IQAI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IQAI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IQAI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IQAI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IQAI's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Trevor Brown (75 yo)
Mr. Trevor Edward Brown, MBA, serves as a an Executive Director of Strategy & Executive Director at Chamberlin plc and served its Non-Executive Director since 2021. He has been the Chief Executive Officer...
CEO Compensation Analysis
Compensation vs Market: Trevor's total compensation ($USD136.49K) is below average for companies of similar size in the UK market ($USD327.60K).
Compensation vs Earnings: Trevor's compensation has increased whilst the company is unprofitable.
Experienced Board: IQAI's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.
IQ-AI Limited's employee growth, exchange listings and data sources
- Name: IQ-AI Limited
- Ticker: IQAI
- Exchange: LSE
- Founded: NaN
- Industry: Health Care Technology
- Sector: Healthcare
- Implied Market Cap: UK£11.407m
- Shares outstanding: 182.51m
- Website: https://www.imagingbiometrics.com/iq-ai-ltd
Number of Employees
- IQ-AI Limited
- Grenville Street
- Forum 4
- Saint Helier
- JE4 8TQ
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/20 21:15|
|End of Day Share Price||2022/01/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.